<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03507738</url>
  </required_header>
  <id_info>
    <org_study_id>MT-5625-01</org_study_id>
    <nct_id>NCT03507738</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and Infants</brief_title>
  <official_title>A Phase 1, Randomized, Placebo-controlled, Descending Age, Dose-escalation Study to Assess the Safety and Immunogenicity of an Investigational Non-Replicating Rotavirus Vaccine (MT-5625) in Healthy Adults, Toddlers and Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to investigate the safety and reactogenicity of MT-5625 independently in adults aged&#xD;
      18-35 years, toddlers ages 12-24 months, and infants aged 6-10 weeks&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 3, 2018</start_date>
  <completion_date type="Actual">June 28, 2019</completion_date>
  <primary_completion_date type="Actual">June 28, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with local reactions and reactogenicity events.</measure>
    <time_frame>Within 7 days after each vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects reporting adverse events.</measure>
    <time_frame>Within 28 days after each vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with anti-MT-5625 IgG seroresponses</measure>
    <time_frame>Day 28 after each vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with neutralizing antibody responses</measure>
    <time_frame>Day 28 after each vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-MT-5625 IgG geometric mean titers (GMTs) 28 days after each injection in adults, toddlers, and infants.</measure>
    <time_frame>Day 28 after each vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing antibody GMTs against rotavirus 28 days after each injection in adults, toddlers and infants.</measure>
    <time_frame>Day 28 after each vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Adult MT-5625 middle dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult receiving intramuscular injection with either middle dose of MT-5625 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adult MT-5625 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult receiving intramuscular injection with either high dose of MT-5625 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Toddler MT-5625 middle dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Toddler receiving intramuscular injection with either middle dose of MT-5625 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Toddler MT-5625 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Toddler receiving intramuscular injection with either high dose of MT-5625 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infant MT-5625 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infant receiving intramuscular injection with either low dose of MT-5625 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infant MT-5625 middle dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infant receiving intramuscular injection with either middle dose of MT-5625 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infant MT-5625 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infant receiving intramuscular injection with either high dose of MT-5625 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rotarix</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infant receiving oral administration with Rotarix</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MT-5625 low dose</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Infant MT-5625 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MT-5625 middle dose</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Adult MT-5625 middle dose</arm_group_label>
    <arm_group_label>Infant MT-5625 middle dose</arm_group_label>
    <arm_group_label>Toddler MT-5625 middle dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MT-5625 high dose</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Adult MT-5625 high dose</arm_group_label>
    <arm_group_label>Infant MT-5625 high dose</arm_group_label>
    <arm_group_label>Toddler MT-5625 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rotarix</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Rotarix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Adult MT-5625 high dose</arm_group_label>
    <arm_group_label>Adult MT-5625 middle dose</arm_group_label>
    <arm_group_label>Infant MT-5625 high dose</arm_group_label>
    <arm_group_label>Infant MT-5625 low dose</arm_group_label>
    <arm_group_label>Infant MT-5625 middle dose</arm_group_label>
    <arm_group_label>Toddler MT-5625 high dose</arm_group_label>
    <arm_group_label>Toddler MT-5625 middle dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or female adults/toddlers/infants as established by medical history and&#xD;
             clinical examination before entering the study&#xD;
&#xD;
          -  Adults aged &gt;18 and &lt; 35, toddlers aged &gt;12 and &lt; 24 months, and infants aged &gt; 6 and&#xD;
             &lt; 10 weeks at the time of enrollment&#xD;
&#xD;
          -  Subject (or Parent/Legal Guardian) willing and able to give written informed consent&#xD;
             after the nature of the study has been explained&#xD;
&#xD;
          -  Subject (or Parent/Legal Guardian) willing to comply with the study restrictions and&#xD;
             study schedule and to remain in the area for the study duration&#xD;
&#xD;
          -  Females of potential childbearing must not be pregnant or breastfeeding and willing to&#xD;
             use adequate method of contraception during the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        ALL SUBJECTS&#xD;
&#xD;
          -  Presence of fever or other acute illness&#xD;
&#xD;
          -  Concurrent participation in another clinical trial or receipt of an investigational&#xD;
             product during the 30 days prior to randomization&#xD;
&#xD;
          -  Suspected or known impairment of immune function&#xD;
&#xD;
          -  Known sensitivity to any components of the study vaccine&#xD;
&#xD;
          -  History of anaphylactic reaction&#xD;
&#xD;
          -  Receipt of immunoglobulin therapy or blood products in last 6 months&#xD;
&#xD;
          -  History of chronic immunosuppressive medications (with the exception of inhaled or&#xD;
             topical steroids)&#xD;
&#xD;
          -  History of any clinically significant disease or disorder which, in the opinion of the&#xD;
             Investigator, may either put the volunteer at risk because of participation in the&#xD;
             study, or influence the results or the volunteer's ability to participate in the study&#xD;
&#xD;
        ADULTS ONLY&#xD;
&#xD;
          -  Have received any vaccine within 4 weeks prior to randomization&#xD;
&#xD;
          -  Any clinically significant illness, medical/surgical procedure, or trauma within 4&#xD;
             weeks of the first administration of investigational product (IP)&#xD;
&#xD;
          -  Any clinically significant abnormalities on 12-lead ECG as judged by the Investigator&#xD;
&#xD;
          -  Any positive result on screening for serum hepatitis B surface antigen, hepatitis C&#xD;
             antibody, and human immunodeficiency virus (HIV) antibody&#xD;
&#xD;
          -  Have any contraindications to parenteral injections ( eg history of bleeding disorder)&#xD;
&#xD;
          -  Known or suspected history of alcohol or drug abuse or excessive intake of alcohol as&#xD;
             judged by the Investigator&#xD;
&#xD;
          -  Donated blood within the 4 weeks prior to randomization&#xD;
&#xD;
        TODDLERS and INFANTS&#xD;
&#xD;
          -  Received any vaccine within 14 days of randomization&#xD;
&#xD;
          -  Presence of malnutrition or other systemic disorders&#xD;
&#xD;
          -  History of congenital abdominal disorders, intussusception or abdominal surgery&#xD;
&#xD;
          -  Major congenital or genetic defect&#xD;
&#xD;
        TODDLERS ONLY&#xD;
&#xD;
          -  Any positive result on screening for serum hepatitis B surface antigen, hepatitis B&#xD;
             core antibody, hepatitis C antibody, and human immunodeficiency virus (HIV) antibody.&#xD;
&#xD;
        INFANTS ONLY&#xD;
&#xD;
          -  Infants with history of premature birth (&lt;37 weeks gestational age)&#xD;
&#xD;
          -  Infants who have received rotavirus vaccine in the past&#xD;
&#xD;
          -  Known sensitivity to any components of the study vaccine, including RotarixÂ®&#xD;
&#xD;
          -  Any positive result on screening for serum hepatitis B surface antigen, hepatitis B&#xD;
             core antibody, and hepatitis C antibody&#xD;
&#xD;
          -  HIV infection assessed by PCR if mother is not known to be negative (negative test&#xD;
             result between 24 weeks gestation and screening).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>General Manager</last_name>
    <role>Study Director</role>
    <affiliation>Mitsubishi Tanabe Pharma Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational center</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational center</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>South Africa</country>
  </location_countries>
  <removed_countries>
    <country>Chile</country>
  </removed_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 15, 2018</study_first_submitted>
  <study_first_submitted_qc>April 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2018</study_first_posted>
  <last_update_submitted>August 4, 2019</last_update_submitted>
  <last_update_submitted_qc>August 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

